Immunosuppressants - Malaysia

Malaysia

The Immunosuppressants market in Malaysia is expected to witness a significant revenue growth, reaching a projected value of US$51.58m in 2024.
This market is anticipated to display a steady annual growth rate of 15.80% from 2024 to 2029, culminating in a market volume of US$107.40m by 2029.
When compared globally, it is noteworthy that United States is forecasted to generate the highest revenue in this sector, amounting to US$35,470.00m in 2024.
The demand for immunosuppressants in Malaysia is steadily rising due to an increase in organ transplant surgeries.

Key regions: Australia, Germany, United Kingdom, United States, France

Market

Region

Region comparison

Currency

Analyst Opinion

The demand for immunosuppressants in Malaysia has been on the rise in recent years.

Customer preferences: Patients in Malaysia who suffer from autoimmune diseases, such as lupus and rheumatoid arthritis, require immunosuppressants to manage symptoms and prevent further damage to their body. Additionally, organ transplant recipients require immunosuppressants to prevent their body from rejecting the transplanted organ.

Trends in the market: In recent years, there has been an increase in the number of organ transplants performed in Malaysia, which has led to a corresponding increase in demand for immunosuppressants. Additionally, the prevalence of autoimmune diseases in Malaysia has been on the rise, which has also contributed to the growth of the immunosuppressants market.

Local special circumstances: One factor that has contributed to the growth of the immunosuppressants market in Malaysia is the country's healthcare system. Malaysia has a well-developed healthcare system that provides affordable and accessible healthcare to its citizens. This has led to an increase in the number of patients seeking treatment for autoimmune diseases and organ transplants, which has, in turn, driven demand for immunosuppressants.

Underlying macroeconomic factors: Malaysia's economy has been growing steadily in recent years, which has led to an increase in disposable income for many Malaysians. This has allowed more people to afford healthcare and has contributed to the growth of the immunosuppressants market. Additionally, Malaysia has a large and growing elderly population, which is more susceptible to autoimmune diseases and organ failure, further driving demand for immunosuppressants.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.